DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub US 2002O187986A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub. Date: Dec. 12, 2002 (54) OPHTHALMIC FORMULATION WHICH Related U.S. Application Data MODULATES DILATION (62) Division of application No. 09/710,758, filed on Nov. (76) Inventor: Gerald Horn, Deerfield, IL (US) 8, 2000, now Pat. No. 6,420,407. Publication Classification Correspondence Address: Bell, Boyd & Lloyd LLC (51) Int. Cl." .................. A61K 31/517; A61K 31/4745; P.O. BOX 1135 A61K 31/4168; A61K 31/4164 Chicago, IL 60690 (US) (52) U.S. Cl. ..................... 514/252.17; 514/283; 514/401 (57) ABSTRACT (21) Appl. No.: 10/165,459 An ophthalmic formulation is disclosed which reduces dila (22) Filed: Jun. 7, 2002 tion in dim light and reduces redness. US 2002/0187986 A1 Dec. 12, 2002 OPHTHALMC FORMULATION WHICH 0007 A formulation for optimizing pupil size in extreme MODULATES DILATION lighting conditions is disclosed. The formulation is prefer ably a Solution of the type used in an artificial tear formu FIELD OF THE INVENTION lation having dissolved therein a therapeutically effective 0001. The present invention relates to a composition amount of a compound characterized by its ability to reduce formulated and administered to a human eye to reduce dilation of the eye, particularly in dim light. The compound dilation and redness. generally interferes with a natural biochemical reaction which results in the stimulation of the dilator muscles of the BACKGROUND OF THE INVENTION eye. The formulation is preferably further comprised of a compound which reduces eye redness, e.g. tetrahydrazolene. 0002 While it is known that pupil size varies in its The compound which has the ability to disrupt endogenous diameter in darkness between individuals from 3 mm to 9 compounds which Stimulate dilator muscles of the eye may mm, little attention has been paid to the effect of this be an alpha 1 antagonist which belongs to a class of difference on the night vision and vision in dim light compounds with phentolamine or phenoxybenzamine (Scotopic vision is dark adapted vision). Those with large groupS. pupils Suffer from much more light Scatter, glare, halo, and related aberrant focus of light rays that can make function 0008 Amethod of optimizing pupil diameter is disclosed under certain conditions of lighting very difficult. wherein the pupil diameter in dim light is effected So that it is not more than 200% greater than its size in bright light. 0.003 Laser vision correction in particular has added new The method encompasses administering a therapeutically quality of vision difficulties for many of these individuals. effective amount of an alpha 1 antagonist to an eye of a Exposing the retina to light focusing from as much as nine perSon in need thereof. The optimized pupil diameter in dim times more Surface area essentially magnifies every varia light may be no more than 5 mm, and the pupil diameter in tion in curvature from the ideal. Currently, only direct acting bright light may be constricted no more than 1 mm. Further, miotic agents Such as pilocarpine are used in an effort to the optimized pupil diameter in dim light may be between decrease pupil size. and including 3 mm and 5 mm and will vary with different 0004 Pilocarpine causes brow ache, ciliary muscle con patients. Actual results with human patients are shown in traction and pseudo myopia, excessive dimneSS when first the Examples. applied, and redness. Its effect lasts only a few hours, and it 0009. In accordance with the method of the invention an has known, though remote, risk of retinal detachment prob application device Such an eyedropper is utilized in order to ably related to pull on the retina from stimulated ciliary apply a therapeutically effective amount of an alpha 1 muscle contraction. For these reasons it is rarely tolerated or agonist to the eye of a patient which is preferably the eye of considered a clinically useful alternative for patients with a human patient. Thereafter, the formulation is allowed to large pupils in dim light. effect the pupil of the eye and contract the pupil So that the 0005 Another medication used to affect pupil size is pupil does not expand above a level which is twice the level dapiprazole, an alpha-1 adrenergic receptor blocking agent of dilation when the eye of the patient is present in bright Dapiprazole is 5,6,7,8-tetrahydro-3-2-(4-O,tolyl-1-piperazi light. Accordingly, another aspect of the invention is a nyl)ethyl-8-triazolo 4,3-alpyridine hydrochloride. It is formulation comprised of an aqueous Solution having an available in a 0.5% solution to partially counteract, or alpha 1 agonist present therein wherein the formulation is reverse, the dilation effect of phenylephrine, an adrenergic present in an eyedropper. dilating agent, and the dilating and accommodation loSS 0010. The present invention is also directed to a method caused by tropicamide. In addition to producing redneSS for optimizing pupil diameter in dim light by minimizing its upon instillation, dapiprazole has very little effect on pupil dilatation in response to leSS light, comprising administering Size in dim light in clinical application when used topically a therapeutically effective amount of an alpha 1 antagonist for this purpose, and therefore its Sole use is as a treatment to an eye of a perSon in need thereof. In this method, of iatrogenically induced mydriasis produced by adrenergic dilatation of the pupil diameter in dim light may be mini or parasympatholytic agents. mized in response to leSS light compared with bright light, SUMMARY OF THE INVENTION and the method may not induce ciliary muscle contraction. 0011. In the method of the present invention, the patient 0006 An ophthalmic formulation of the invention pref may Suffer from excessively large pupils in dim light, and erably obtains two simultaneous effects (a) reducing the the patient may Suffer from poor quality of vision, and the amount of dilation the eye would normally undergo in a low patient may be undergoing medication that results in dila light environment; and (b) reducing eye redness. Reducing tation of the pupil diameter. Alternatively, the pupil diameter normal dilation can be obtained by administering a com of the patient may be naturally excessively dilated as a result pound which interferes with the normal stimulation of of response to dimming of light. muscles which cause dilation. This can be done, for example, with an alpha 1 antagonist. However, redness may 0012. The method of the invention may be carried out by be reduced using an alpha 1 agonist. The antagonist and directly instilling onto the eye an eye drop formulation of the agonist will, in general, counteract each other. The present invention. Optionally, the alpha 1 antagonist may be admin invention provides a particularly preferred formulation of (a) istered by contacting a contact lens, and the contact lens an alpha 1 antagonist which is phentolamine; and (b) an applied to the eye. In the method of the invention, the used alpha 1 agonist which is tetrahydrozoline and Specifically alpha 1 antagonist preferably may belong to a class of tetrahydrozoline hcl. This combination reduces dilation and compounds belonging to the phentolamine or phenoxyben redness. Zamine groups. US 2002/0187986 A1 Dec. 12, 2002 0013 The present invention is directed to a method for is the formulation of the invention present within an appli reducing pupil diameter in dim light in cases where dilation cation device Such as a conventional or improved eyedrop of the pupil is excessive, Such as 6 mm or greater. Admin per of the type described herein. istering a formulation of the invention does not induce ciliary contraction or undesirable pseudomyopia that may 0019. An advantage of the invention is that it can be result from taking certain medication. Formulations dis utilized to treat patients who have been Subjected to laser closed here reverse mydriasis of parasympatholytic agents. Surgery and have developed a range of different vision Formulations of the invention are effective on agents para problems as a result of excessive dilation of their pupils. lyzing accommodation Such as 1% cylogyl, which can then 0020. A feature of the invention is that the alpha 1 be used for more complete cycloplegia and accurate prelaser antagonist can be formulated in a manner which is readily refractive measurement. administered to the eye to obtain a desired effect. 0.014. There are no generally available eye drops for 0021. These and other aspects, advantages and features of optimizing pupil Size Such as by reducing pupil diameter in the invention will become apparent to those skilled in the art dim light without undesirable side effects. The present upon reading this disclosure. invention recognizes that the alpha-1 antagonists which are currently used for treatment of high blood pressure, treat DETAILED DESCRIPTION OF THE ment of pheochromocytoma, migraines, bladder Spasm, INVENTION prostate enlargement, and Sexual dysfunction can be formu 0022. Before the present formulations and methods are lated used in reducing pupil diameter. described, it is to be understood that this invention is not 0.015 The present invention provides an ophthalmic limited to particular compounds, formulas or Steps composition which achieves the combined requirements of described, as Such may, of course, vary. It is also to be understood that the terminology used herein is for the comfort and pupil diameter optimization. purpose of describing particular embodiments only, and is 0016 Alpha adrenergic receptor antagonists function to not intended to be limiting, Since the Scope of the present block alpha-1 receptor mediated contraction of arterial and invention will be limited only by the appended claims.
Load more

Recommended publications
  • Totalcare Medicaid 2017 Q2 GB
    Preferred Drug List Molina Healthcare of New York, Inc. 2017 *Molina mandates the use of generic drugs, if available. Brand names listed are for reference only. THIS LIST IS SUBJECT TO CHANGE. You can get more information and updates to this document on our website at www.molinahealthcare.com MCD_CO_ESIPREFDRUGQ3_0817_08/27/2017 6025633NY0417 Table of Contents Anti - Infectives....................................................................................................................................................3 Antineoplastic / Immunosuppressant Drugs ......................................................................................................12 Autonomic / Cns Drugs, Neurology / Psych ......................................................................................................17 Cardiovascular, Hypertension / Lipids...............................................................................................................34 Dermatologicals/Topical Therapy......................................................................................................................41 Diagnostics / Miscellaneous Agents ..................................................................................................................56 Ear, Nose / Throat Medications..........................................................................................................................64 Endocrine/Diabetes ............................................................................................................................................66
    [Show full text]
  • Pharmacology of Ophthalmic Agents
    Ophthalmic Pharmacology Richard Alan Lewis M.D., M.S., PHARMACOLOGY FOPS PHARMACOKINETICS OF Professor, Departments of Ophthalmology, • The study of the absorption, OPHTHALMIC Medicine, Pediatrics, and Molecular distribution, metabolism, AGENTS and Human Genetics and excretion of a drug or and the National School of Tropical agent Introduction and Review Medicine Houston, Texas PHARMACOKINETICS Factors Affecting Drug Penetration Factors Affecting Drug Penetration into Ocular Tissues • A drug can be delivered to ocular tissue: into Ocular Tissues – Locally: • Drug concentration and solubility: The higher the concentration the better the penetration, • Surfactants: The preservatives in ocular • Eye drop but limited by reflex tearing. preparations alter cell membrane in the cornea • Ointment and increase drug permeability, e.g., • Viscosity: Addition of methylcellulose and benzalkonium and thiomersal • Periocular injection polyvinyl alcohol increases drug penetration by • pH: The normal tear pH is 7.4; if the drug pH is • Intraocular injection increasing the contact time with the cornea and altering corneal epithelium. much different, it will cause reflex tearing. – Systemically: • Lipid solubility: Because of the lipid rich • Drug tonicity: When an alkaloid drug is put in • Orally environment of the epithelial cell membranes, relatively alkaloid medium, the proportion of the uncharged form will increase, thus more • IM the higher lipid solubility, the more the penetration. • IV penetration. FLUORESCEIN FLUORESCEIN Chemistry Dosage ● C20H1205, brown crystal ● Adults: 500-750 mg IV ● M.W. 322.3 e.g., 3 cc 25% solution ● Peak absorption 485-500 nm. 5 cc 10% solution ● Peak emission 520-530 nm. ● Children: 1.5-2.5 mg/kg IV Richard Alan Lewis, M.D., M.S.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Accommodation of Three Regimens of Topical Dapiprazole Br J Ophthalmol: First Published As 10.1136/Bjo.79.6.544 on 1 June 1995
    544 British Journal of Ophthalmology 1995; 79: 544-548 Comparison of the effects on pupil size and accommodation of three regimens of topical dapiprazole Br J Ophthalmol: first published as 10.1136/bjo.79.6.544 on 1 June 1995. Downloaded from Charles S Wilcox, Jon F Heiser, Anna Mae Crowder, Nancy J Wassom, Barbara B Katz, Jacqueline L Dale Abstract mydriasis induced by sympathomimetic Background-Patients who have their agents, such as phenylephrine, and parasympa- pupils dilated for an eye examination tra- tholytics, such as tropicamide, dapiprazole also ditionally have to wait several hours shows a beneficial effect on loss of accommo- before their pupils return to normal size dation,1 although the exact mechanism for its and their blurred vision (caused by paral- effect on accommodation is unknown. In most ysis of accommodation) resolves. Earlier patients, reversal of mydriasis and improve- studies with dapiprazole have demon- ment in accommodation begin within 15 strated an accelerated reversal of dilata- minutes of administration of the drug. tion. Since its introduction, dapiprazole has been Methods-Three regimens of dapiprazole used in a 2+2 regimen, two drops followed by were studied to determine the effects on two more drops 5 minutes later. In clinical pupil diameter and accommodation after practice, returning to dose the patient for a mydriasis produced by 2.5% phenyl- second time in 5 minutes can sometimes be ephrine and 0.5% tropicamide. Test troublesome for both the ophthalmologist and regimens included one drop and 1 + 1 the patient. After a review of the literature on drop regimens, compared with a 2 +2 drop dapiprazole, Doughty and Lyle2 suggested that reference regimen.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • PAPER SPRAY MASS SPECTROMETRY for RAPID DRUG SCREENING by Rachel Jett
    PAPER SPRAY MASS SPECTROMETRY FOR RAPID DRUG SCREENING by Rachel Jett A Thesis Submitted to the Faculty of Purdue University In Partial Fulfillment of the Requirements for the degree of Master of Science Department of Chemistry Indianapolis, Indiana August 2017 ii THE PURDUE UNIVERSITY GRADUATE SCHOOL STATEMENT OF COMMITTEE APPROVAL Dr. Nick Manicke, Chair Department of Chemistry and Chemical Biology Dr. John Goodpaster Department of Chemistry and Chemical Biology Dr. Michael McLeish Department of Chemistry and Chemical Biology Approved by: Dr. Eric C. Long Head of the Graduate Program iii To the Creator- Who places the mysteries of the world before us and the curiosities of the mind within us iv ACKNOWLEDGMENTS This project would not have been possible without the input, support, and feedback of the Manicke and Goodpaster Groups: Nick, Chengsen, Brandon, Greta, Josiah, Grace, John, Dana, Will, Jordan, Clinton Thank you. v TABLE OF CONTENTS LIST OF TABLES ........................................................................................................... viii LIST OF FIGURES ............................................................................................................ x LIST OF ABBREVIATIONS .......................................................................................... xiv ABSTRACT ................................................................................................................. xv CHAPTER 1: BACKGROUND ........................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]